Human cytomegalovirus (HCMV) is the major infectious cause of birth defects and a significant cause of morbidity and mortality in transplant and AIDS patients. Efforts to vaccinate against CMV disease have centered on a live attenuated strain Towne vaccine. The discovery that HCMV encodes four proteins that block antigen presentation by down- regulating class I expression on infected cells suggest that possibility that deleting these genes from the vaccine strain might induce a more robust immune response by enhancing presentation of viral antigens to the host immune system. However, this might also result in more rapid clearance of the virus and hence attenuate the overall immune response. Thus, the consequences of modifying the Towne vaccine are difficult to predict. Because HCMV does not infection animals, viruses such as murine, rat and guinea pig cytomegalovirus (GPCMV) have been studied as animal models; however, only GPCMV is transmitted in utero and causes birth defects similar to those of HCMV. Evidence for class I down-regulation has been reported for both the rat and murine viruses, and preliminary evidence from our laboratory suggests that GPCMV also down-regulates class I. The goals of this project are to identify the GPCMV genes responsible for class I down-regulation and characterize the mechanisms by which down-regulation occurs.. These preliminary in vitro studies will provide the basis from which to construct recombinant GPCMVs in which the class I down-regulation genes have been deleted, and this will permit future in vivo studies to test the efficacy of live vaccines based on these engineered viruses as well as the importance of these genes for viral pathogenesis. Ultimately, these results should help to guide the construction of improved HCMV vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31AI010537-02
Application #
6372933
Study Section
Special Emphasis Panel (ZRG1-RPHB-3 (02))
Program Officer
Hernandez, Milton J
Project Start
2001-07-01
Project End
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
2
Fiscal Year
2001
Total Cost
$24,921
Indirect Cost
Name
Virginia Commonwealth University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Askenase, Phillip W; Bryniarski, Krzysztof; Paliwal, Vipin et al. (2015) A subset of AID-dependent B-1a cells initiates hypersensitivity and pneumococcal pneumonia resistance. Ann N Y Acad Sci 1362:200-14
Bryniarski, Krzysztof; Ptak, Wlodzimierz; Jayakumar, Asha et al. (2013) Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol 132:170-81
Askenase, P W; Majewska-Szczepanik, M; Kerfoot, S et al. (2011) Participation of iNKT cells in the early and late components of Tc1-mediated DNFB contact sensitivity: cooperative role of ??-T cells. Scand J Immunol 73:465-77
Lacayo, Juan; Sato, Hiroshi; Kamiya, Haruo et al. (2003) Down-regulation of surface major histocompatibility complex class I by guinea pig cytomegalovirus. J Gen Virol 84:75-81